Search

Search Constraints

You searched for: Author/Creator Beyne-Rauzy, O.

Search Results

1. 109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS. (April 2015)

2. 14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION. (April 2015)

3. 148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS. Issue 1 (April 2015)

4. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Issue 1 (April 2015)

5. 81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES. (April 2015)

9. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents. (April 2017)

10. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Issue 8 (August 2015)